Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Kolltan Also Appoints Paul Medeiros to the Company's Board of Directors and Appoints Roy S. Herbst, M.D., Ph.D., and Thomas Mehrling, M.D., Ph.D., to the Company's Scientific Advisory Board
NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the appointment of Carolyn F. Sidor, M.D., as Senior Vice President and Chief Medical Officer. Dr. Sidor will report to Dr. Jerry McMahon, Kolltan's President and Chief Executive Officer. In addition, Kolltan announced today the appointments of Paul Medeiros to the Company's Board of Directors and Roy Herbst, M.D., Ph.D., and Thomas Mehrling, M.D., Ph.D., to the Company's Scientific Advisory Board.
"She brings a strong background in patient care, clinical research planning and implementation of clinical trials. Carolyn will be instrumental to advance our drug pipeline into human clinical testing, the first of which is planned to commence next year."
"We are very pleased that Carolyn will be joining Kolltan as Chief Medical Officer in our expanded management team," commented Dr. McMahon. "She brings a strong background in patient care, clinical research planning and implementation of clinical trials. Carolyn will be instrumental to advance our drug pipeline into human clinical testing, the first of which is planned to commence next year."
Dr. Sidor is a board-certified hematologist/medical oncologist with more than 30 years of clinical, regulatory, and drug development experience over multiple therapeutic areas including oncology, hematology, and inflammatory diseases. Prior to joining Kolltan, she most recently served as a consultant to the biotechnology industry after serving as Vice President and Chief Medical Officer at EntreMed. During her tenure at EntreMed, she was responsible for the direction, design, and execution of research and development activities for drugs and biologics from discovery through Phase 2 studies. Previously, she served as Vice President, Scientific and Medical Development at Cato Research Ltd. where she led projects from IND through NDA. Dr. Sidor ran a hematology/medical oncology practice at University of North Carolina Hospitals until 2012 and has been the author or co-author of more than 30 presentations, publications and abstracts on clinical research. She received her M.D. degree from Thomas Jefferson University and M.B.A. degree from the University of Delaware, as well as a B.S. degree from the New York State College of Forestry at Syracuse University.
Dr. Sidor stated, "Kolltan has assembled a leading team in oncology with a substantial track record. I am excited to join the team's efforts to advance the research and clinical development of novel cancer therapies, and in particular, to lead the development of Kolltan's lead program, KTN3379, an innovative monoclonal antibody targeting ErbB3 receptor tyrosine kinase."
Dr. McMahon commented, "In addition to further expanding our senior management team, we have allied with key leaders in the advancement of new approaches to oncology, and we are very pleased with the additions of Paul Medeiros to our Board of Directors and Dr. Roy Herbst and Dr. Thomas Mehrling to our Scientific Advisory Board."
Mr. Medeiros is Head of Corporate and Business Development at Mundipharma International. Previously, he served as Senior Vice President and Chief Business Officer at AVI BioPharma (now, Sarepta Therapeutics). Prior to this, Mr. Medeiros served as Vice President, Global Licensing and Strategic Alliances for Schering-Plough, where he led worldwide product licensing and strategic partnering initiatives in specialist product categories. Mr. Medeiros began his biopharmaceutical career at Merck & Company, where he held positions in new product planning and worldwide marketing. Mr. Medeiros holds an A.B. with honors from Brown University and an M.B.A. from Columbia Business School.
Dr. Herbst is the Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, and Chief of the Section of Medical Oncology in the Department of Internal Medicine at Yale School of Medicine. Additionally, he serves as Associate Director for Translational Research at Yale Cancer Center. He is a leader in adaptively randomized tissue-based clinical trial design and has led the Phase 1 development of several new generation targeting agents for non-small-cell lung and head and neck carcinoma, including gefitinib, cetuximab, erlotinib, and bevacizumab. Previously, he was the Barnart Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas M.D. Anderson Cancer Center. Dr. Herbst is an NCI-funded investigator and the author or co-author of more than 250 publications in prominent journals such as Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. After earning B.S. and M.S. degrees from Yale University summa cum laude, he completed his M.D. degree at Cornell University Medical College and earned his Ph.D. degree in molecular cell biology from the Rockefeller University. He also completed medical oncology training at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, including an M.S. degree in Clinical Translational Research from Harvard University.
Dr. Mehrling is a board-certified physician and pharmacist/pharmacologist and is Managing Director of Mundipharma EDO GmbH, which is developing early-stage oncology assets as an independent associated company within the Mundipharma Group. Previous positions at Mundipharma included Director of International Strategy & Alliance Management for Oncology and Director European Oncology. Prior to this, he held the position of Vice President Medical and Regulatory Affairs at Staticon International, a global clinical research organization, and Clinical Leader at the Takeda Research & Development Centre Europe. Dr. Mehrling received his M.D. degree as well as his Ph.D. degree in pharmacological science from the Johann Wolfgang Goethe-Universität, Frankfurt am Main.
About Kolltan Pharmaceuticals
Kolltan, a privately held company, is advancing a new generation of therapeutics in oncology and other diseases by creating novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has a unique understanding of RTKs, their ligands, and cellular signaling and has assembled a team with significant expertise and unique insight into these drug targets. Kolltan's senior management has a track record of success in bringing products to patients and significant value to shareholders. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is advancing a new generation of therapeutics in oncology and other diseases, in collaboration with the laboratory of Kolltan founder, Dr. Joseph Schlessinger. The Company's breakthrough R&D pipeline is advancing rapidly, with the first clinical trial program anticipated to begin in the first half of 2014.
For more information about Kolltan Pharmaceuticals, please visit www.kolltan.com.
Burns McClellan, on behalf of Kolltan Pharmaceuticals
Justin Jackson, 212-213-0006